title: Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
abstract: Dalbavancin is an antimicrobial lipoglycopeptide agent that has proven activity against Gram-positive pathogens and a once weekly dosing advantage compared with other agents in the glycopeptide class. The most common pathogens isolated from skin and skin structure infections (SSSIs) include Staphylococcus aureus and beta-hemolytic streptococci (betaHS), and dalbavancin has demonstrated excellent activity against these species. This study used 18 medical center laboratories in 5 European countries to assess the activity of dalbavancin, vancomycin, and teicoplanin against S. aureus, coagulase-negative staphylococci (CoNS), and betaHS. The rank order of potency was dalbavancin (MIC(50), 0.06 microg/mL) > teicoplanin (MIC(50), 0.5 microg/mL) > vancomycin (MIC(50), 2 microg/mL) and dalbavancin (MIC(50), 0.06 microg/mL) > teicoplanin and vancomycin (MIC(50), 2 microg/mL) against S. aureus and CoNS, respectively. Dalbavancin was the most active glycopeptide tested against betaHS with all strains inhibited by < or = 0.12 microg/mL. Susceptibility to other antimicrobial classes was also evaluated with noticeable differences demonstrated between countries. Higher methicillin-resistant S. aureus (MRSA) rates were observed in Italy (44.2%) and the United Kingdom (36.8%) compared with other countries, but resistance to erythromycin (51.6-83.1%) and clindamycin (5.7-68.4%) among MRSA also varied significantly between countries. The excellent contemporary activity of dalbavancin against common Gram-positive pathogens collected in European countries suggests that dalbavancin could have a role in the treatment of various types of SSSIs.
authors.affiliation: JMI Laboratories, North Liberty, IA 52317, USA. douglas-biedenbach@jmilabs.com
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Biedenbach
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D005060:Europe; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects*; D013290:Streptococcal Infections / Q000382:microbiology; D013291:Streptococcus / Q000187:drug effects*; D017334:Teicoplanin / Q000031:analogs & derivatives* / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D014640:Vancomycin; C469289:dalbavancin